You decide

Quote












anonymous said:
MT was the winner here. He showed class and professionalism! The short seller looked like a scam artist!
Click to expand...

Still, this is not good press on Mallinckrodt and not only hard on Acthar reps. This is severely hurting the hospital division and has done enormous damage. Not sure how MT was shown as a winner.
 












anonymous said:
MT was the winner here. He showed class and professionalism! The short seller looked like a scam artist!
Click to expand...

Left may be a scam artist but read the article in Chest Journal. MT and MNK leadership are the true con men (snake oil salesmen) and you are a corporate shill. Do a study to prove your claims and then you might be able to justify the ridiculous asking price for acthar...unless you are afraid of what the study might reveal.
 






























the more he tries the worse he looks and the less credible he seems in my opinion. Stock is probably where it should be, Questcor buy was a disaster, overpaid for smoke and mirrors. Cadence probably a decent deal nothing earth shattering but screwed it up due tolack of leadership and direction. Homostasis products still scratching head over that one. Wanting to get rid of imaging because doesn't fit platform okay can buy it. Deciding to hold onto nuclear because it brings cash to pay for all the other mistakes and EOC's bonuses is hypocritical but its business.

Didn't they have a survey that was supposed to show how everything is great?
 






Prescribing treatments such as H.P. Acthar Gel, when there is no evidence for marginal effectiveness at any cost, let alone $25,000 a month above a standard alternative, is wasteful and unprofessional. We applaud Dr Metersky for drawing our attention to this issue, and calling out this question for our profession and our nation.
 






True Dough said:
Prescribing treatments such as H.P. Acthar Gel, when there is no evidence for marginal effectiveness at any cost, let alone $25,000 a month above a standard alternative, is wasteful and unprofessional. We applaud Dr Metersky for drawing our attention to this issue, and calling out this question for our profession and our nation.
Click to expand...

Your math is off for most indications, as $25,000 a month isn't even close. One vial will get you 2 and 1/2 weeks of treatment at 80 units, a common dosing. 4-5 vials over 3 months is closer to 60k a month. It's disgusting.
 






anonymous said:
so you are relying on an editorial to dispute scientific evidence?
Click to expand...


Did you bother to look at the credentials of the authors? Not good when someone from P&T of one of the countries largest payers writes into a prestigious journal like CHEST.
Your truck loads of scientific evidence (note sarcasm) obviously has underwhelmed them
 












True Dough said:
Prescribing treatments such as H.P. Acthar Gel, when there is no evidence for marginal effectiveness at any cost, let alone $25,000 a month above a standard alternative, is wasteful and unprofessional. We applaud Dr Metersky for drawing our attention to this issue, and calling out this question for our profession and our nation.
Click to expand...

Pleeeeease give us a break!!!!!!! Live how you make it sound like you're a physician or something. Go to hell you big dork rep.
 


















The criticism arises because we don't spend on R&D like other companies, try to claim me-too drugs are innovative, basically have no real internal pipeline for novel products (or even a real R&D division) and have bought products and simply raised prices. That used to be a good model when no one was looking, but that ship has sailed thanks to Valeant and Valeant clones like us and Endo. We are going to be the subject of bad press until something dramatic happens, more dramatic than TV cameos for the CEO.
 






Top Bottom
Back
Quote